HGS selects Veeva CRM to support launch of Lupus drug in Europe
Veeva CRM will help HGS with all specialty care sales reps and medical science liaisons in Germany, Spain and France. According to HGS, Veeva’s pharmaceutical industry expertise and
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The double-blind, multicentre, placebo-controlled, randomised CUV030 study was designed to assess the safety and efficacy of subcutaneous bioresorbable afamelanotide implants in reducing phototoxic skin reactions in erythropoietic protoporphyria